Peregrine Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Peregrine Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-171,291	Closed	-$9.16M	–	340
2020 Q4	$9.16M	Sell	171,291 -16,798	-9%	-$834K	0.17%	236
2020 Q3	$7.76M	Sell	188,089 -37,568	-17%	-$1.62M	0.21%	158
2020 Q2	$10.9M	Sell	225,657 -183,297	-45%	-$8.8M	0.31%	123
2020 Q1	$17.3M	Buy	408,954 +37,177	+10%	+$1.53M	0.62%	54
2019 Q4	$15.9M	Sell	371,777 -22,476	-6%	-$978K	0.41%	114
2019 Q3	$14.2M	Sell	394,253 -144,025	-27%	-$4.37M	0.39%	118
2019 Q2	$14.4M	Sell	538,278 -1,166	-0.2%	-$29.8K	0.36%	125
2019 Q1	$14.5M	Sell	539,444 -140,161	-21%	-$3.27M	0.36%	126
2018 Q4	$11M	Sell	679,605 -73,709	-10%	-$1.43M	0.31%	135
2018 Q3	$15.6M	Buy	+753,314	New	+$11.9M	0.37%	124

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Peregrine Capital Management's ACAD Position: Q1 2021 in Review

Peregrine Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 171,291 shares — an estimated $9.16M sold.

Peregrine Capital Management first reported a position in ACAD in Q3 2018 and held it in 10 quarters. The position peaked at $17.3M in Q1 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Peregrine Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Peregrine Capital Management sold 171,291 Acadia Pharmaceuticals shares in Q1 2021, an estimated $9.16M.
Peregrine Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Peregrine Capital Management's Acadia Pharmaceuticals position peaked at $17.3M in Q1 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Peregrine Capital Management's 13F filing for Q1 2021, filed 11 May 2021.